Eidogen-Sertanty Licenses Target Informatics Platform to AstraZeneca
News Dec 16, 2005
Eidogen-Sertanty, Inc. has announced that AstraZeneca Pharmaceuticals LP has licensed access to its Target Informatics Platform™.
Under the agreement, scientists at AstraZeneca R&D Boston will access Eidogen-Sertanty’s Target Informatics Platform (TIP™) and EVE™ Comparative Visualization software to assist drug discovery efforts within their cancer and anti-infective therapeutic programs.
Through the integration of protein structural data and ligand binding site analysis, TIP is designed to bridge the knowledge gap between the disciplines of bioinformatics and cheminformatics.
"We are very excited that AstraZeneca R&D Boston has selected TIP to assist their drug discovery efforts," said Dr. Steve Muskal, CEO of Eidogen-Sertanty.
"We’re confident that TIP will help AstraZeneca scientists accelerate lead discovery programs across a wide variety of target families and therapeutic areas."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019